Immunome (IMNM) Other Operating Expenses (2023 - 2025)

Immunome's Other Operating Expenses history runs 3 years deep, the most recent figure standing at $10.0 million for Q4 2025.

• Quarterly Other Operating Expenses fell 63.47% year-over-year to $10.0 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $10.0 million (down 75.24% YoY) and the FY2025 annual result came in at $10.0 million, down 93.44% from the prior year.
• Other Operating Expenses was $10.0 million for Q4 2025 at Immunome, down from $27.4 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $112.0 million in Q1 2024 and bottomed at $6.3 million in Q2 2024.
• A 3-year average of $40.5 million and a median of $18.7 million in 2024 frame the typical range for Other Operating Expenses.
• Annual changes were most pronounced in 2024 — Other Operating Expenses tumbled 66.12% — and 2025, when it slumped 63.47%.
• Immunome's Other Operating Expenses stood at $80.8 million in 2023, then tumbled by 66.12% to $27.4 million in 2024, then slumped by 63.47% to $10.0 million in 2025.
• Business Quant data shows IMNM's Other Operating Expenses at $10.0 million in Q4 2025, $27.4 million in Q4 2024, and $6.7 million in Q3 2024.